United States· US:72893-001_cbc2c428-cff7-4ea6-abee-f3ea7ff5a65f

EVOMELA

A melphalan product containing melphalan hydrochloride, registered in United States by Acrotech Biopharma Inc. The same ATC class is registered in 17 of our 19 countries.

ATC L01AA03

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedEVOMELAATCL01AA03REGISTER NO.US:72893-001_cbc2c428…PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Melphalan is registered in 17 of 19 countries.

Countries holding a registration under ATC L01AA03 (melphalan), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 10 of them publish a price we can compare per daily dose

Melphalan · ATC L01AA03

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of melphalan costs, country by country.

Normalised to the WHO defined daily dose (2 mg), the median price runs from $0.79 in Italy to $3.83 in Switzerland — a ×4.8 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Melphalan · price per daily dose (2 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$3.83
  • FR France$0.89
  • IT Italy$0.79
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
MELPHALAN HYDROCHLORIDE
Manufacturer
Acrotech Biopharma Inc
Country
United States (US)
ATC code
L01AA03
ATC class
Melphalan
Defined daily dose
2 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 1

  • ndc11
    72893-001-01

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

242 interactions on record for melphalan.

Graded by severity as the source publishes them — 32 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Melphalan · interactions on record

242 records

  • 32 severe
  • 100 moderate
  • 25 minor
  • 85 info

Most severe, free to view

  • Nalidixic acidJ01MB02severe
  • ThiotepaL01AC01severe
  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Melphalan in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All melphalan products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Alkeran, Melphalan Hikma
  • Belgium · Alkeran, Melfalan Tillomed
  • Cyprus · Melfalan Tillomed
  • Czechia · Alkeran, Melphalan Zentiva
  • Germany · Alkeran, Melphalan
  • Denmark · Alkeran, Melphalan Macure
  • Estonia · Alkeran
  • Spain · Alkeran, Melfalán Aspen
  • Finland · Alkeran, Melphalan Macure
  • France · Alkeran, Melphalan Hikma
  • United Kingdom (Northern Ireland) · Melphalan, Melphalan Accord-Uk
  • Greece · Demephan, Melphalan Tillomed
  • Croatia · Melfalan Pliva, Melfalan Tillomed
  • Hungary · Melphalan Teva, Melphalan Zentiva
  • Ireland · Alkeran, Melphalan Tillomed
  • Iceland · Alkeran, Phelinun
  • Italy · Alkeran, Melfalan Hikma
  • Liechtenstein · Phelinun
  • Lithuania · Alkeran, Melphalan Zentiva
  • Luxembourg · Alkeran, Melphalan Aqvida
  • Latvia · Alkeran, Melphalan Tillomed
  • Netherlands · Alkeran, Melfalan Amarox
  • Norway · Alkeran, Melphalan Macure
  • Poland · Alkeran, Melphalan Zentiva
  • Portugal · Alkeran, Melfalano Eugia
  • Romania · Alkeran, Melfalan Teva
  • Sweden · Alkeran, Melfalan Sun
  • Slovenia · Alkeran, Melfalan Teva
  • Slovakia · Alkeran, Melphalan Zentiva

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0e91e5e8-b6fc-4fbf-81a2-0428aacccb34
GET /v1/drugs/0e91e5e8-b6fc-4fbf-81a2-0428aacccb34?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "INTRAVENOUS",
  "source": "ndc",
  "strength": "50",
  "substance": "MELPHALAN HYDROCHLORIDE",
  "productndc": "72893-001",
  "dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
  "dea_schedule": null,
  "strength_unit": "mg/10mL",
  "application_number": "NDA207155",
  "marketing_category": "NDA"
}

See everything about melphalan.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.